Literature DB >> 25878327

The investigation and management of metabolic myopathies.

Simon Edward Olpin1, Elaine Murphy2, Richard James Kirk3, Robert William Taylor4, Rosaline Quinlivan5.   

Abstract

Metabolic myopathies (MM) are rare inherited primary muscle disorders that are mainly due to abnormalities of muscle energy metabolism resulting in skeletal muscle dysfunction. These diseases include disorders of fatty acid oxidation, glyco(geno)lytic muscle disorders and mitochondrial respiratory chain (MRC) disease. Clinically these disorders present with a range of symptoms including infantile hypotonia, myalgia/exercise tolerance, chronic or acute muscle weakness, cramps/spasms/stiffness or episodic acute rhabdomyolysis. The precipitant may be fasting, infection, general anaesthesia, heat/cold or most commonly, exercise. However, the differential diagnosis includes a wide range of both acquired and inherited conditions and these include exposure to drugs/toxins, inflammatory myopathies, dystrophies and channelopathies. Streamlining of existing diagnostic protocols has now become a realistic prospect given the availability of second-generation sequencing. A diagnostic pathway using a 'rhabdomyolysis' gene panel at an early stage of the diagnostic process is proposed. Following detailed clinical evaluation and first-line investigations, some patients will be identified as candidates for McArdle disease/glycogen storage disease type V or MRC disease and these will be referred directly to the specialised services. However, for the majority of patients, second-line investigation is best undertaken through next-generation sequencing using a 'rhabdomyolysis' gene panel. Following molecular analysis and careful evaluation of the findings, some patients will receive a clear diagnosis. Further functional or specific targeted testing may be required in other patients to evaluate the significance of uncertain/equivocal findings. For patients with no clear diagnosis, further investigations will be required through a specialist centre. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  ENZYMES; INHERITED PATHOLOGY; METABOLISM; MOLECULAR GENETICS; MUSCLE

Mesh:

Substances:

Year:  2015        PMID: 25878327     DOI: 10.1136/jclinpath-2014-202808

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

Review 1.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

2.  A novel HADHA variant associated with an atypical moderate and late-onset LCHAD deficiency.

Authors:  Anne-Frédérique Dessein; Eléonore Hebbar; Joseph Vamecq; Elodie Lebredonchel; Aurore Devos; Jamal Ghoumid; Karine Mention; Dries Dobbelaere; Marie Joncquel Chevalier-Curt; Monique Fontaine; Sabine Defoort; Vassily Smirnov; Claire Douillard; Claire-Marie Dhaenens
Journal:  Mol Genet Metab Rep       Date:  2022-03-15

3.  Recurrent Muscle Weakness with Rhabdomyolysis, Metabolic Crises, and Cardiac Arrhythmia Due to Bi-allelic TANGO2 Mutations.

Authors:  Seema R Lalani; Pengfei Liu; Jill A Rosenfeld; Levi B Watkin; Theodore Chiang; Magalie S Leduc; Wenmiao Zhu; Yan Ding; Shujuan Pan; Francesco Vetrini; Christina Y Miyake; Marwan Shinawi; Tomasz Gambin; Mohammad K Eldomery; Zeynep Hande Coban Akdemir; Lisa Emrick; Yael Wilnai; Susan Schelley; Mary Kay Koenig; Nada Memon; Laura S Farach; Bradley P Coe; Mahshid Azamian; Patricia Hernandez; Gladys Zapata; Shalini N Jhangiani; Donna M Muzny; Timothy Lotze; Gary Clark; Angus Wilfong; Hope Northrup; Adekunle Adesina; Carlos A Bacino; Fernando Scaglia; Penelope E Bonnen; Jane Crosson; Jessica Duis; Gustavo H B Maegawa; David Coman; Anita Inwood; Jim McGill; Eric Boerwinkle; Brett Graham; Art Beaudet; Christine M Eng; Neil A Hanchard; Fan Xia; Jordan S Orange; Richard A Gibbs; James R Lupski; Yaping Yang
Journal:  Am J Hum Genet       Date:  2016-01-21       Impact factor: 11.025

Review 4.  Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases.

Authors:  Anthony Tucker-Bartley; Jordan Lemme; Andrea Gomez-Morad; Nehal Shah; Miranda Veliu; Frank Birklein; Claudia Storz; Seward Rutkove; David Kronn; Alison M Boyce; Eduard Kraft; Jaymin Upadhyay
Journal:  Neurosci Biobehav Rev       Date:  2021-02-10       Impact factor: 9.052

5.  Carnitine Palmitoyltransferase II Deficiency (CPT II) Followed By Rhabdomyolysis and Acute Kidney Injury.

Authors:  Nikola Gjorgjievski; Pavlina Dzekova-Vidimliski; Zvezdana Petronijevic; Gjulsen Selim; Petar Dejanov; Liljana Tozija; Aleksandar Sikole
Journal:  Open Access Maced J Med Sci       Date:  2018-04-12

Review 6.  Update Review about Metabolic Myopathies.

Authors:  Josef Finsterer
Journal:  Life (Basel)       Date:  2020-04-17

7.  Recurrent rhabdomyolysis caused by carnitine palmitoyltransferase II deficiency, common but under-recognised: Lessons to be learnt.

Authors:  M Balasubramanian; T M Jenkins; R J Kirk; I M Nesbitt; S E Olpin; M Hill; G T Gillett
Journal:  Mol Genet Metab Rep       Date:  2018-03-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.